105. Efficacy of Cariprazine in Patients With Schizophrenia Based on Stage of Illness

ABSTRACT: Abstract Background: Cariprazine (CAR) is a D3/D2 receptor partial agonist antipsychotic approved for treatment of adults with acute exacerbation of schizophrenia. Many patients with schizophrenia display a progressive worsening of symptomatology, a process that has the potential to impede treatment response. These post hoc analyses were performed to evaluate CAR efficacy in subsets of patients at different stages of disease progression. Methods: Data were pooled from 3 randomized, 6-week, double-blind, placebo (PBO)-controlled Phase II/III trials of CAR efficacy and safety in patients with schizophrenia (NCT01104766, NCT01104779, NCT00694707). For this post hoc analysis, data were grouped according to number of previous episodes (<5, 5–10, >10), duration of schizophrenia in years (≤5.1, 5

SUBMITTER: Mofsen R 

PROVIDER: S-EPMC5475603 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature